Found 429 clinical trials
A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab,or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
refractory B-cell lymphoma.
- 86 views
- 10 May, 2022
- 21 locations
A safety and Tolerability Study of INCB053915 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma
The purpose of this study is to evaluate the safety and tolerability of INCB053914 in combination with INCB050465 in relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).
- 95 views
- 10 May, 2022
- 2 locations
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma
- 61 views
- 17 Sep, 2023
- 112 locations
Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis (Bio-CHIC)
large B-cell lymphoma (DLBCL).
- 44 views
- 31 Jan, 2022
- 16 locations
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
This Phase Ib, open-label, multicenter study evaluates the safety, efficacy, and pharmacokinetics of venetoclax in combination with Pola + R-CHP in previously untreated participants with BCL-2 IHC-positive DLBCL. Approximately 50 participants will be enrolled in this study in five consecutive cohorts each consisting of approximately 10 participants.
- 6 views
- 11 Sep, 2023
- 17 locations
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
This study consists of a dose escalation/confirmation phase and an efficacy expansion phase. The dose escalation/confirmation phase is to determine the safety and tolerability and establish a preliminary recommended Phase 2 dose (RP2D) of zilovertamab vedotin when administered in combination with R-CHP in participants with DLBCL who have received no …
- 0 views
- 19 Sep, 2023
- 19 locations
Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)
chemotherapy (C2), on the probability of obtaining a metabolic complete response after 4 cycles of induction chemotherapy (C4) in patients with primary mediastinal large B cell lymphoma (PMBL) receiving
- 0 views
- 09 Apr, 2021
- 2 locations
CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma
, China) infusion following ASCT in patients with relapsed or refractory B-cell lymphoma.
- 0 views
- 23 Mar, 2022
- 1 location
Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel
The aim of this non-interventional multi-center study is to evaluate quality of life (QOL) and other patient reported outcomes (PROs) among adults with diffuse large b-cell lymphoma (DLBCL
- 0 views
- 29 Apr, 2022
- 1 location
Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma
-Hodgkin's B cell lymphoma (r/r B-NHL).
- 0 views
- 11 Nov, 2021
- 1 location